Oxaliplatin immunohybrid nanoparticles in vitro synergistic suppression evaluation in treatment of colorectal cancer

References

• Alexis F, Pridgen E, Molnar LK, Farokhzad OC. 2008. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 5:505–515.
   PubMed Web of Science ®Google Scholar
• Altieri DC. 2003. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3:46–54.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Leroux JC. 2012. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release. 161:152–163.
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. 2008. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 60:1615–1626.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Misset JL. 2002. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 29:11–20.
   PubMed Web of Science ®Google Scholar
• Chuah LH, Roberts CJ, Billa N, Abdullah S, Rosli R. 2014. Cellular uptake and anticancer effects of mucoadhesive curcumin-containing chitosan nanoparticles. Colloids Surf B. 116:228–236.
   PubMed Web of Science ®Google Scholar
• Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F. 2010. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release. 144:324–331.
   PubMed Web of Science ®Google Scholar
• Fujie Y, Yamamoto H, Ngan CY, Takagi A, Hayashi T, Suzuki R, et al. 2005. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. JpnJ Clin Oncol. 35:453–463.
   Web of Science ®Google Scholar
• Gupta A, Kaur CD, Saraf S, Saraf S. 2015. Formulation, characterization, and evaluation of ligand-conjugated biodegradable quercetin nanoparticles for active targeting. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. doi: 10.3109/21691401.2015.1008503.
   Web of Science ®Google Scholar
• Hashimoto Y, Endoh H, Sugawara M. 1984. Chemical methods for the modification of liposomes with proteins or antibodies. Liposome Technol. 3:41–50.
   Google Scholar
• Heath TD, Martin FJ. 1986. The development and application of protein-liposome conjugation techniques. Chem Phys Lipids. 40:347–358.
   PubMed Web of Science ®Google Scholar
• Holoch PA, Griffith TS. 2009. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol. 625:63–72.
   PubMed Web of Science ®Google Scholar
• Hosseini M, Haji-Fatahaliha M, Jadidi-Niaragh F, Majidi J, Yousefi M. 2015. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. doi: 10.3109/21691401.2014.998830.
   Web of Science ®Google Scholar
• Jaiswal P, Gidwani B, Vyas A. 2014. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol. 44:27–40.
   PubMed Web of Science ®Google Scholar
• Kirkin V, Joos S, Zörnig M. 2004. The role of Bcl-2 family members in tumorigenesis. BBA-Mol Cell Res. 1644:229–249.
   PubMed Web of Science ®Google Scholar
• Krishnaiah Y, Satyanarayana S. 2001. Colon-specific drug delivery systems. Advances in controlled and novel drug delivery. New Delhi, India: CBS Publishers and Distributors. pp. 89–119.
   Google Scholar
• Leserman LD, Machy P, Barbet J. 1984. Covalent coupling of monoclonal antibodies and protein A to liposomes: specific interaction with cells in vitro and in vivo. Liposome Technol. 3:29–40.
   Google Scholar
• Lin PH, Zui P, Zheng L, Na L, Danielpour D, Jie J. 2005. Overexpression of Bax sensitizes prostate cancer cells to TGF-beta induced apoptosis. Cell Res. 15:160–166.
   PubMed Web of Science ®Google Scholar
• Michor F, Iwasa Y, Lengauer C, Nowak MA. 2005. Dynamics of colorectal cancer. Semin Cancer Bio. 15:484–493.
   PubMed Web of Science ®Google Scholar
• Nair KL, Jagadeeshan S, Nair SA, Kumar GS. 2011. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int J Nanomed. 6:1685–1697.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2:751–760.
   PubMed Web of Science ®Google Scholar
• Smits VA, Medema RH. 2001. Checking out the G(2)/M transition. 2M transition. BBA Gene Struct Expr. 1519:1–12.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. 1984. Immobilization of specific proteins on liposome surface: systems for drug targeting. Liposome Technol. 3:75–94.
   Google Scholar
• Tummala S, Gowthamarajan K, Satish Kumar M, Wadhwani A. 2015. Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors. Drug Deliv. [Epub ahead of print]. doi: 10.3109/10717544.2015.1084400.
   Web of Science ®Google Scholar
• Tummala S, Kumar MS, Gowthamarajan K, Prakash A, Rama K, Raju S, Mulukutla S. 2014. Preparation, physicochemical characterization and in vitro evaluation of oxaliplatin solid lipid nanoparticles for the treatment of colorectal cancer. Indo Amer J Pharm Res. 4:3579–3587.
   Google Scholar
• Tummala S, Kumar MS, Prakash A. 2014. Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J. 23:308–314.
   PubMed Web of Science ®Google Scholar
• Tummala S, Gowthamarajan K, Satish Kumar M, Praveen TK, Yamjala K, Tripuraneni NS, Prakash A. 2015. Formulation and optimization of oxaliplatin immun-nanoparticles using Box–Behnken design and cytotoxicity assessment for synergistic and receptor mediated targeting in the treatment of colorectal cancer. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. doi: 10.3109/21691401.2015.1111226.
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. 1999. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo. Nat Med. 5:157–163.
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. 2009. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 8:129–138.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Hu AB, Cui SZ, Wei HB. 2012. Thermotherapy enhances oxaliplatin-induced cytotoxicity in human colon carcinoma cells. World J Gastroenterol. 18:646–653.
   PubMed Web of Science ®Google Scholar